Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
申请人:HEPAREGENIX GMBH
公开号:US11040027B2
公开(公告)日:2021-06-22
The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
本发明涉及 MKK4(丝裂原活化蛋白激酶 4)及其在促进肝脏再生或减少或防止肝细胞死亡方面的用途。MKK4 抑制剂选择性地抑制蛋白激酶 MKK4,而不是蛋白激酶 JNK 和 MKK7。